First reported by EU-Startups
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
Alchemab Therapeutics extends Series A with £25m investment
From the article
Alchemab Therapeutics has extended its Series A financing with £25m from the British Business Bank, marking the Bank’s largest investment in a life sciences company to date. Founded in 2019, Alchemab is a clinical-stage biotechnology company that discovers and develops novel antibody therapeutics by identifying naturally occurring protective antibodies in individuals who show resilience to […] The post Alchemab Therapeutics extends Series A with £25m investment appeared first on UKTN .
Continue reading on UKTNYou might also wanna read
Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet
EU-Startups·11h ago
AdBiotech Becomes No. 2 Shareholder of Pet Healthcare Firm Onhil
Seoul Economic Daily·3d ago
RQ Bio secures $115M Series A for virus-targeting antibody pipeline
endpoints.news·15d agoNovartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Fierce Biotech·3d ago
Biotech venture capital roundup: Osanni Bio leads with $190M Series B
A roundup of recent venture capital financings in the biotech sector, headlined by Osanni Bio's $190 million Series B round to fund drug can
pharmaphorum.com·13d ago
Alp Bio's AI platform predicts immune reactions to biologic drugs earlier in development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
vist.ly·13d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.